¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"squamous cell carcinoma antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • cuboidal cell
    ÀԹ漼Æ÷, ÁÖ»çÀ§¼¼Æ÷
  • cylindrical cell
    ¿øÁÖ¼¼Æ÷
  • cytotoxic cell
    ¼¼Æ÷µ¶¼º¼¼Æ÷
  • cytotoxic cell protein
    ¼¼Æ÷µ¶¼º¼¼Æ÷´Ü¹éÁú
  • cytotoxic killer T cell
    ¼¼Æ÷µ¶¼º»ìÇØT¼¼Æ÷
  • cell
    ¼¼Æ÷
  • cell adhesion molecule
    ¼¼Æ÷ºÎÂøºÐÀÚ
  • cell agar plate
    ¼¼Æ÷¿ì¹«ÆòÆÇ
  • cell bank
    ¼¼Æ÷ÀºÇà
  • cell body
    ¼¼Æ÷ü
  • cell color ratio
    ÀûÇ÷±¸»ö¼Òºñ
  • cell culture
    ¼¼Æ÷¹è¾ç
  • cell cycle
    ¼¼Æ÷ÁÖ±â
  • cell death
    ¼¼Æ÷»ç
  • cell dedifferentiation
    ¼¼Æ÷Å»ºÐÈ­
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • cell envelope
    ¼¼Æ÷²®Áú
  • cell fusion
    ¼¼Æ÷À¶ÇÕ
  • cell hybridization
    ¼¼Æ÷ºÎÇÕÈ­, ¼¼Æ÷ÇÏÀ̺긮µåÈ­
  • cell inclusion
    ¼¼Æ÷Æ÷ÇÔ¹°
  • cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ë
  • cell lethality
    ¼¼Æ÷Ä¡»çÀ²
  • cell line
    ¼¼Æ÷°è, ¼¼Æ÷ÁÖ
  • cell loss
    ¼¼Æ÷¼Ò½Ç
  • cell mass
    ¼¼Æ÷µ¢ÀÌ
  • cell membrane
    ¼¼Æ÷¸·
  • cell organelle
    ¼¼Æ÷¼Ò±â°ü
  • cell respiration
    ¼¼Æ÷È£Èí
  • cell strain
    ¼¼Æ÷ÁÖ
  • cell substitution
    ¼¼Æ÷´ëÄ¡, Ç÷±¸´ëÄ¡
  • cell swelling
    ¼¼Æ÷Á¾Ã¢
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • group-specific antigen
    ±º-ƯÀÌÇ׿ø
  • hepatitis B core antigen (HBc Ag)
    BÇü °£¿°¹ÙÀÌ·¯½º ÇÙ½ÉÇ׿ø
  • hepatitis B surface antigen (HBs Ag)
    BÇü °£¿°¹ÙÀÌ·¯½º Ç¥¸éÇ׿ø
  • hepatitis B surface antigen(HBs Ag)
    BÇü °£¿°Ç¥¸éÇ׿ø
  • heterogenetic antigen
    ÀÌÁ¾Ç׿ø.
  • heterologous antigen
    ÀÌÁ¾Ç׿ø
  • heterophil(e) antigen
    ÀÌÁ¾Ä£È­(¼º) Ç׿ø(¡­ù÷ê«).
  • heyman antigen
    ÇÏÀ̸¸ Ç׿ø, Heyman Ç׿ø
  • hidden antigen
    ÀºµÐÇ׿ø, ÀºÆóÇ׿ø
  • histocompatibility antigen
    Á¶Á÷ÀûÇÕÇ׿ø
  • histocompatibility antigen, major
    ÁÖÁ¶Á÷ÀûÇÕÇ׿ø
  • homologous antigen
    »óµ¿Ç׿ø.
  • i antigen
    i Ç׿ø
  • immunogen (antigen)
    ¸é¿ª¿ø(Øóæ¹ê«).
  • inaccessible antigen
    ¿ø°ÝÇ׿ø(êÀ̰ù÷ê«), ÀáÀçÇ׿ø.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • spongy carcinoma ³ª c. spongiosum
    ÇØ¸é¾ç¾ÏÁ¾(ú­ØúåÆäßðþ)
  • stomach,carcinoma
    ¾ÏÁ¾(äßðþ)
  • subcutaneous carcinoma
    ÇÇÇÏ ¾Ï(Á¾)
  • superior sulcus carcinoma
    Æó÷±¸¾ÏÁ¾(øËôÓ±¸äßðþ)
  • superior sulcus tumor(carcinoma)=pancoast tumor
    »ó±¸¾ÏÁ¾
  • sweat gland carcinoma
    ÇѼ± ¾Ï(Á¾)
  • syringoid carcinoma
    ÇѰü¾ç ¾ÏÁ¾
  • syringoid eccrine carcinoma
    ÇѰü¾ç ¿¡Å©¸° ¾Ï(Á¾)
  • telangiectatic carcinoma
    ¸ð¼¼Ç÷°ü È®Àå ¾Ï(Á¾)
  • thymic carcinoma
    Èä¼±¾ÏÁ¾(¡­ ðþ)
  • thyroid carcinoma
    °©»ó¼±¾ÏÁ¾(¡­äßðþ)
  • trichilemmal carcinoma
    ¸ð³¶ ¾Ï(Á¾)
  • tubular carcinoma
    °ü»ó¾ÏÁ¾(ηßÒ ðþ)
  • undifferentiated carcinoma
    ¹ÌºÐÈ­¾ÏÁ¾(Ú±ÝÂûùäßðþ)
  • urothelial carcinoma
    ¿ä·Î»óÇǾÏÁ¾(èñÖØß¾ù«äßðþ)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
  • Pole of cell
    ¼¼Æ÷±Ø
    [¿¾ ¿ë¾î] ¼¼Æ÷±Ø
  • Cell cycle
    ¼¼Æ÷ÁÖ±â
    [¿¾ ¿ë¾î] ¼¼Æ÷ÁÖ±â
  • Border cell
    ¼Ó°æ°è¼¼Æ÷
    [¿¾ ¿ë¾î] ³»°æ°è¼¼Æ÷
  • Goblet cell
    ¼úÀܼ¼Æ÷
    [¿¾ ¿ë¾î] ¹è»ó[Á¡¾×]¼¼Æ÷
  • Neurosensory cell
    ½Å°æ°¨°¢¼¼Æ÷
    [¿¾ ¿ë¾î] ½Å°æ°¨°¢¼¼Æ÷
  • Neurosensory cell body
    ½Å°æ°¨°¢¼¼Æ÷ü
    [¿¾ ¿ë¾î] ½Å°æ°¨°¢¼¼Æ÷ü
  • Nerve cell [Neuron]
    ½Å°æ¼¼Æ÷ [½Å°æ´ÜÀ§]
    [¿¾ ¿ë¾î] ½Å°æ¼¼Æ÷
  • Nerve cell body
    ½Å°æ¼¼Æ÷ü
    [¿¾ ¿ë¾î] ½Å°æ¼¼Æ÷ü
  • Cone cell
    ¿ø»Ô¼¼Æ÷
    [¿¾ ¿ë¾î] Ãß»óü½Ã¼¼Æ÷
  • Serous cell
    Àå¾×¼¼Æ÷
    [¿¾ ¿ë¾î] Àå¾×¼¼Æ÷
  • Germ cell
    Á¾ÀÚ¼¼Æ÷
    [¿¾ ¿ë¾î] Á¾¼¼Æ÷
  • Glomus cell
    Å丮¼¼Æ÷
    [¿¾ ¿ë¾î] ±¸»ó¼¼Æ÷
  • Tendon cell
    ÈûÁÙ¼¼Æ÷
    [¿¾ ¿ë¾î] °Ç¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 15
FLC family life cycle; fatty liver cell; fetal liver cell; Friend leukemia cell
GCT general care and treatment; germ-cell tumor; giant cell thyroiditis; giant cell tumor
SCM Schwann cell membrane; sensation, circulation, and motion; Society of Computer Medicine; soluble cyt...
TCE T-cell enriched; tetrachlorodiphenyl ethane; trichloroethylene T-cell thymus-derived cell
TCR T-cell reactivity; T-cell receptor; T-cell rosette; thalamocortical relay; total cytoplasmic ribosom...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 15
PCNA LI proliferating cell nuclear antigen labeling index
3-LL 3-Lewis lung carcinoma
AIS Adeno-carcinoma in situ
ACC Adenoid Cystic Carcinoma
ACC Adrenocortical carcinoma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cell substitution
    ¼¼Æ÷ ġȯ, Ç÷±¸ Àç»ý
  • cell surface marker
    ¼¼Æ÷ Ç¥¸é Ç¥ÁöÀÚ
  • cell survival curve
    ¼¼Æ÷ »ýÁ¸ °î¼±
  • cell transfer
    ¼¼Æ÷ ÀÌÀÔ
    Á¼Àº Àǹ̿¡¼­´Â °¢Á¾ ¼¼Æ÷¸¦ ¹æ»ç¼± Á¶»ç µîÀÇ Ã³¸®¸¦ °¡ÇÑ µ¿¹°¿¡ ÁÖÀÔÇϰí ÁÖÀÔµÈ ¼¼Æ÷ÀÇ ¼º»óÀ» Á¶»çÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÑ ¼¼Æ÷ ÁÖÀÔÀÇ ¹æ¹ýÀ» °¡¸®Å°¸ç in vitro¿¡¼­ ¼¼Æ÷ ±â´ÉÀ» Á¶»çÇϱⰡ °ï¶õÇÑ °æ¿ì, in vivo¿¡¼­ÀÇ ¹ÝÀÀ¼ºÀ» Á¶»çÇÏ°í ½ÍÀº °æ¿ì, ¶Ç chimera mouse¸¦ Á¦ÀÛÇÒ ¶§¿¡ »ç¿ëµÈ´Ù. ³ÐÀº Àǹ̿¡¼­´Â ¼¼Æ÷°¡ ÇÑÆí¿¡¼­ ´Ù¸¥ ÆíÀ¸·Î À̵¿ÇÏ´Â °ÍÀ» °¡¸®Å²´Ù.
  • cell typing
    Ç÷±¸Çü °Ë»ç
  • cell wall
    ¼¼Æ÷ º®
    µ¿ÀǾî=cell membrane.
  • cell wall inhibitor
    ¼¼Æ÷ º® ÇÕ¼º ¾ïÁ¦Á¦
  • cell wall teichoic acid
    ¼¼Æ÷ º® ŸÀÌÄÚ»ê
  • cell,hydropic degeneration
    ¼öÆ÷¼º º¯¼º
  • cell-mediated cytotoxicity
    ¼¼Æ÷ ¸Å°³¼º ¼¼Æ÷ µ¶¼º
    Ç×ü ȤÀº lym
  • cell-mediated hypersensitivity
    ¼¼Æ÷ ¸Å°³¼º °ú¹ÎÁõ
    TuberculinÇü Çdz» ¹ÝÀÀÀ» ´ëÇ¥·Î ÇÑ´Ù. ¼¼Æ÷¼º ¸é¿ª ¹ÝÀÀÀÇ ÇÑ ÇüÅÂ. Ç׿ø¿¡ ÀÇÇÏ¿© °¨ÀÛµÈ µ¿¹°ÀÇ Çdz»¿¡ ÀçÂ÷ Ç׿øÀ» ÁÖ»çÇÔÀ¸·Î½á ¼ö ½Ã°£À¸·ÎºÎÅÍ 36½Ã°£ ÈÄ¿¡ ¹ßÀû, °æ°áÀ» ¼ö¹Ý½ÃŰ´Â Á¾Ã¢ÀÌ ÁÖ»ç ºÎÀ§¿¡ ¹ß»ýÇÏ´Â ¹ÝÀÀÀÌ´Ù.
  • cell-mediated immunity
    ¼¼Æ÷ ¸Å°³ ¸é¿ª, ¼¼Æ÷ ¸Å°³¼º ¸é¿ª
  • cell-mediated immunodeficiency syndrome
    ¼¼Æ÷¼º ¸é¿ª °áÇÌ ÁõÈıº
  • central giant cell
    °ñ³» °Å´ë ¼¼Æ÷
  • central giant cell tumor
    Á߽ɼº °Å´ë ¼¼Æ÷ ¾ÏÁ¾
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 15
major histocompatibility antigen <immunology> A set of plasmalemmal glycoprotein antigens involved in rapid (e.g. 7 days in the mouse) graft rejection and other immune phenomena. The minor histocompatibility antigens are involved in much slower rejection phenomena. The major antigens show remarkable polymorphism and occur as Class I and Class II types in mammals, birds may have a Class III molecule as well.
See: histocompatibility antigens, MHC restriction.
(18 Nov 1997)
P antigen <haematology, immunology> Antigenic determinant on the surface of human red blood cells to which the Donath Landsteiner antibody reacts.
This antibody binds in the cold (a cold IgG), but elutes from red cells at 37­C, is particularly associated with tertiary syphylis and its binding causes paroxysmal nocturnal haemoglobinuria.
(18 Nov 1997)
R antigen Those that produce active haemolysins (O and S) which cause a zone of clear haemolysis on the blood agar medium in the area of the colony; beta-haemolytic streptococci are divided into groups (A to O) on the basis of cell wall C carbohydrate (see Lancefield classification); Group A (in the strains pathogenic for man) comprises more than 50 types (designated by Arabic numerals) determined by cell wall M protein, which seems to be associated closely with virulence and is produced chiefly by strains with matt or mucoid colonies, in contrast to nonvirulent, glossy colony-producing strains; other surface protein antigens such as R and T (T substance), and the nucleoprotein fraction (P substance) seem to be of less importance. The more than 20 extracellular substances elaborated by strains of beta-haemolytic streptococci include erythrogenic toxin (elaborated only by lysogenic strains), deoxyribonuclease (streptodornase), haemolysins (streptolysins O and S), hyaluronidase, and streptokinase.
Synonym: haemolytic streptococci.
(05 Mar 2000)
M antigen An antigen found in the cell of Streptococcus pyogenes; associated with virulence.
See: beta-haemolytic streptococci.
(05 Mar 2000)
receptors, antigen Molecules on the surface of b- and T-lymphocytes that recognise and combine with specific antigens.
(12 Dec 1998)
receptors, very late antigen Members of the integrin family appearing late after T-cell activation. They are a family of proteins initially identified at the surface of stimulated T-cells, but now identified on a variety of cell types. At least six vla antigens have been identified as heterodimeric adhesion receptors consisting of a single common beta-subunit and different alpha-subunits.
(12 Dec 1998)
Gerbich antigen glycophorin C
Vi antigen Virulence antigen, an external capsular antigen of enterobacteria formerly thought to be related to increased virulence.
(05 Mar 2000)
partial antigen <immunology, molecular biology> Could be considered an isolated epitope: although a hapten (by definition) has an antibody directed against it, the hapten alone will not induce an immune response if injected into an animal, it must be conjugated to a carrier (usually a protein).
The hapten constitutes a single antigenic determinant, perhaps the best known example is dinitro phenol (DNP) that can be conjugated to BSA and against which antiDNP antibodies are produced (antibodies to the BSA can be adsorbed out).
Because the hapten is monovalent, immune complex formation will be blocked if the soluble hapten is present as well as the hapten carrier conjugate (assuming there is more than one hapten per carrier then an immune precipitate can be formed).
Competitive inhibition by the soluble small molecule is sometimes referred to as haptenic inhibition and this term has carried over into lectin mediated haemagglutination where monosaccharides are added to try to block haemagglutination: the blocking sugar defines the specificity of the lectin.
(18 Nov 1997)
viral antigen Those antigens specified by the viral genome (often coat proteins) that can be detected by a specific immunological response. Often of diagnostic importance.
(18 Nov 1997)
C carbohydrate antigen An antigen found in the cell wall of Streptococcus pneumoniae.
See: beta-haemolytic streptococci.
(05 Mar 2000)
CD antigen <immunology> Differentiation antigens residing on human leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similiar reactivity with certain subpopulations of antigens. The subpopulations of antigens are also known by the same CD designation.
(12 Dec 1998)
Rhus toxicodendron antigen An extract of fresh leaves of poison ivy, with 0.4% of procaine hydrochloride; used by intradermal injection to determine sensitiveness to the poison of Rhus toxicodendron.
(05 Mar 2000)
Rhus venenata antigen An extract of fresh leaves of poison sumac; used to determine sensitiveness to the plant or to relieve the dermatitis caused by contact with its leaves.
(05 Mar 2000)
cholesterinised antigen Cardiolipin to which cholesterol has been added.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 15
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 15
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 15
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 15
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 15
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 15
ÅëÇÕ°Ë»ö ¿Ï·á